These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24647572)

  • 1. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
    Lin F; de Gooijer MC; Roig EM; Buil LC; Christner SM; Beumer JH; Würdinger T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2014 May; 20(10):2703-13. PubMed ID: 24647572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.
    Lentzas A; de Gooijer MC; Zuidema S; Meurs A; Çitirikkaya CH; Venekamp N; Beijnen JH; van Tellingen O
    Fluids Barriers CNS; 2024 Aug; 21(1):62. PubMed ID: 39103921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.
    Lin F; de Gooijer MC; Hanekamp D; Chandrasekaran G; Buil LC; Thota N; Sparidans RW; Beijnen JH; Würdinger T; van Tellingen O
    Clin Cancer Res; 2017 Mar; 23(5):1286-1298. PubMed ID: 27553832
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
    Parrish KE; Cen L; Murray J; Calligaris D; Kizilbash S; Mittapalli RK; Carlson BL; Schroeder MA; Sludden J; Boddy AV; Agar NY; Curtin NJ; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2015 Dec; 14(12):2735-43. PubMed ID: 26438157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.
    Li J; Wu J; Bao X; Honea N; Xie Y; Kim S; Sparreboom A; Sanai N
    Clin Cancer Res; 2017 Dec; 23(24):7454-7466. PubMed ID: 28928160
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.
    Lin F; Buil L; Sherris D; Beijnen JH; van Tellingen O
    Int J Cancer; 2013 Sep; 133(5):1222-33. PubMed ID: 23436212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.
    Mittapalli RK; Chung AH; Parrish KE; Crabtree D; Halvorson KG; Hu G; Elmquist WF; Becher OJ
    Mol Cancer Ther; 2016 May; 15(5):819-29. PubMed ID: 26883271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and
    Verheijen RB; Yaqub M; Sawicki E; van Tellingen O; Lammertsma AA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR; Hendrikse NH; Steeghs N
    J Nucl Med; 2018 Jun; 59(6):973-979. PubMed ID: 29175983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
    Zhang P; de Gooijer MC; Buil LC; Beijnen JH; Li G; van Tellingen O
    Int J Cancer; 2015 Oct; 137(8):2007-18. PubMed ID: 25868794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme.
    Radtke L; Majchrzak-Celińska A; Awortwe C; Vater I; Nagel I; Sebens S; Cascorbi I; Kaehler M
    Pharmacol Res; 2022 Nov; 185():106510. PubMed ID: 36252775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.